[16,17] Concurrently, the integrase cuts the cellular DNA, and the sticky ends of the viral ... vectors of the genera gammaretroviruses, lentiviruses and foamy viruses have been used for gene ...

Cardiovascular disease remains the foremost cause of morbidity and mortality globally, affecting millions of individuals. Recent discoveries illuminate the substantial role of genetics in ...

Approximately three-quarters of the more than 2,000 current gene therapy trials use viral vectors owing to their ... issuing a material transfer agreement, and produces msDNA for each licensee.

There has been significant progress in the development of safe and effective viral and non-viral vectors for gene transfer.

Cryoport’s IntegriCell Belgium site will transfer its developed optimised cryopreservation ... that can maintain consistent ...

CAGR offers a clear view of long-term investment trends by balancing fluctuations for a steady growth rate. BCC Research reveals exciting growth opportunities, with specific industries poised for ...

In this Thought Leader article., Ian Johnston from Cytiva discusses challenges related to process development, scaling technology, regulatory approvals, and GMP guidelines.

Still, the potential for a one-time gene transfer therapy is real.” Boys who receive the treatment can experience a variety of side effects due to their bodies receiving millions of viral particles ...

Our in-stock adenoviral vectors are available per vial of 500 ul ... Ad5-CMV-CBR-luciferase This adenovirus expresses the Click Beetle Red (CBR) luciferase gene developed by Promega. The ...

Roche will apply Dyno Therapeutics’ engineered adeno-associated virus (AAV) capsid platform to develop next-generation AAV vectors for gene therapies targeting unspecified neurological diseases ...

New strategic partnership leverages the power of the Dyno platform, enabling Roche to advance next-generation AAV gene therapies across multiple targets Dyno to receive US$50 million upfront cash ...